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Molecular dockingAbstract In the present investigation synthesis of some novel 1-(2-(1H-benzimidazol-2-yl)phenyl)-
3-chloro-4-(Un/substitutedphenyl)azetidin-2-one (3a–3h) is reported. All these compounds were
characterized by IR, Mass, 1H NMR and elemental analysis. The newly synthesized compounds
were screened for analgesic and anti-inﬂammatory activities on acetic acid induced writhing in mice
and carrageenan induced paw edema in rats. Compound 3 g was found to have potent analgesic
(46% at 20 mg/kg b.w) and anti-inﬂammatory (66.5% at 20 mg/kg b.w) activities as compared to
standard drug nimesulide (20 mg/kg b.w). To check binding modes and binding afﬁnity of synthe-
sized compounds were docked into the active sites of enzyme COX-II. Compounds 3a, 3e and 3 h
were found to have good afﬁnity for COX-II. A good correlation is found between in silico docking
analysis and in biological screening.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Benzimidazoles and their analogs are well known biologically
activeN-containing heterocycles (Kozo et al., 2001), widely usedas drugs such as proton pump inhibitor (Omeprazole) (Langtry
andWilde, 1998), antihelmentic (Albendazole) (Hazelton et al.,
1995), and anti-dopaminergic Domperidone (Kennis et al.,
1986) anti-psychotic (Pimozide) (Meisel et al., 1987). Speciﬁ-
cally, the 2-substituted analogs of benzimidazoles are known
to be potent biologically active compounds (Kazimierczuk
et al., 2005) Apart from these benzimidazole nucleus is also
found to be a part of analgesic and anti-inﬂammatory agents
(Sondhi et al., 2002; Zheng et al., 2007; Sondhi et al., 2006; Kav-
itha et al., 2010; Charlson, 1975). Azetidinones have attracted
much attention owing to their important pharmacological
properties; a large numbers of azetidinones were reported to
possess anti-inﬂammatory activity (Agarwal et al., 1989;
S1780 S.S. Chhajed, C.D. UpasaniSrivastava et al., 2000). In the light of these observations
this prompted us to synthesize a new series of benzimidazole
derivatives by incorporating the azetidinonemoiety at 2nd posi-
tion of benzimidazole nucleus. In the present work, synthesis of
some novel 1-(2-(1H-benzimidazol-2-yl)-phenyl)-3-chloro-4-
[un/substituted phenyl]-azetidin-2-ones is reported. The struc-
tures of all compounds have been evaluated by elemental
analysis and spectral analysis (IR and 1H NMR). All the com-
pounds have been screened for their analgesic and anti-inﬂam-
matory activity. In-silico molecular docking analysis of
synthesized scaffold into the active site of enzyme cyclooxygen-
ase is carried out.
2. Results and discussion
2.1. Chemistry
Target compounds 3a–3h were prepared by synthetic protocol
described in Scheme 1. 2-(1H-benzimidazol-2-yl)benzenamine
(2) was synthesized by reﬂuxing orthophenylenediamine with
anthranilic acid in the presence of polyphosphoric acid. Ob-
tained, compound 2 was then reﬂuxed with different aromatic
aldehydes in the presence of sulfuric acid to form Schiff bases
(2a–2h). Resultant Schiff bases were cyclized to form 2-azetid-
inones 3a–3h with chloro acetyl chloride in the presence of tri-
ethylamine in dry 1,4-dioxane. Triethylamine was used to
absorb released hydrochloric acid. All reactions were moni-
tored by analytical thin layer chromatography. The structures
of synthesized compounds were conﬁrmed by IR, MS and 1H
NMR spectroscopy. The IR spectra of compounds 2a–2h
provide valuable information regarding the nature of func-
tional group present in the structure of compounds. The bands
around 1595–1610 cm1 suggested the presence of azomethine
linkage in the compounds. The 1H NMR spectra for com-
pounds 2a–2h showed a single peak for the azomethine
ACH‚N proton, which varied in its position. The signals of
1H NMR and IR were in complete agreement with the as-
signed structures to compounds 3a–3h. From the IR spectraNH2
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Scheme 1 Synthetic protocol for the target compounds 3a–3h.
Reagents: (a) anthranilic acid, polyphosphoric acid, reﬂux 4 h; (b)
H2SO4, different aldehydes reﬂux; (c) 1,4 dioxane, chloroacetic
acid, tryethylamine, reﬂux.of compounds 3a–3h, it can be concluded that the absence of
stretching frequencies for azomethine linkage afforded the
cyclization. The presence of >C‚O peak around
1650–1750 cm1 in the IR spectrum, conﬁrms the achievement
of cyclic amide ring in the compounds 3a–3h. The mass spectra
of these compounds displayed a molecular ion peak at appro-
priate m/z values which were corresponding well with the
respective molecular formulas. All the compounds have given
the satisfactory elemental analysis by C, H and N.
2.2. Pharmacology
2.2.1. Statistical analysis
Results of all the above estimations have been indicated in
terms of mean ± SEM. Difference between the groups was
statistically determined by analysis of variance (ANOVA) with
Dunnett’s test multiple comparisons test. The level of signiﬁ-
cance was set at P < 0.05.
2.2.2. Experimental animals
Albino rats of Wistar strain (150–200 g) and Swiss albino mice
(25–30 g) of either sex were used in the entire study and were
procured from Yash farm, Pvt. Ltd, Pune, India. They were
housed in standard polypropylene cages and kept under con-
trolled room temperature (24 ± 2 C; relative humidity
60–70%) in a 12 h light–dark cycle. The animals were fed with
standard laboratory diet and water ad libitum. Food was with-
drawn 12 h before and during the experimental hours. The
experimental protocol was approved by Institutional Animal
Ethics Committee. All rats treated with different compounds
up to 250 mg kg1 were alive during the 24 h of observation.
These animals did not show visible signs of acute toxicity.
The tested compounds are considered non-toxic up to dose
250 mg/kg.
2.2.3. Analgesic activity
Pain reactivity was measured by the writhing test of Koster
et al. Koster and Anderson (1959) The test was performed in
mice by i.p. injection of a 0.6% acetic acid (1.0 ml/kg i.p.)
60 min after the administration of compounds. Each com-
pound was administrated orally as a suspension of 1% Tween
80 of 20 mg kg1. Control groups received an equal volume of
vehicle. Each experimental group consisted of ﬁve animals.
Animals were placed in glass cages 5 min after acetic acid injec-
tion and number of writhes per animal was counted in the
following 20 min. Nimesulide (20 mg/kg, p.o.) was used as a
reference drug. Percentage protection against writhing was
taken as an index of analgesia. Results are summarized in
the Table 1.
2.2.4. Anti-inﬂammatory activity
Synthesized compounds 3a–3h were tested for their in vivo
anti-inﬂammatory efﬁcacy using carrageenan-induced paw
edema method (Winter et al., 1962). The tested compounds
and the standard drug nimesulide produced signiﬁcant
reduction of paw size as compared to the control group. Rats
in groups of ﬁve each were treated with vehicle, synthesized
compounds 3a–3h (20 mg/kg, p.o.) one hour prior to Carra-
geenan injection. 0.1 ml of 1% Carrageenan was injected into
the sub plantar tissue of left hind paw of each rat. Swellings
of carrageenan injected foot were measured at 0, 1, 2, 3 h using
Plethysmometer (UGO Basile, Italy). The right hind paw was
Table 1 Analgesic activity of tested compounds (20 mg/kg
b.w) and Nimesulide (20 mg/kg b.w).
Treatment Number of Writhing % Inhibition
Control 63.2 ± 1.020 –
Nimesulide 30 ± 1.183** 52.54
3a 39.6 ± 3.66** 37.34
3b 48.4 ± 1.94** 26.32
3c 50.6 ± 0.40** 19.93
3d 44.2 ± 1.114** 30.06
3e 34 ± 2.34** 46.20
3f 46 ± 1.897** 27.21
3g 49.2 ± 0.583** 22.15
3h 35.6 ± 0.509** 43.67
Data represent mean values SEM of ﬁve mice per group, shown at
the ﬁnal value for each group (control, nimesulide and tested
compounds) after 1 h.
Data were analyzed using one-way ANOVA followed by Dunnett
test.
** p < 0.01.
Synthesis and in-silico molecular simulation S1781injected with 0.1 ml of vehicle. Nimesulide (20 mg/kg p.o.) was
used as reference agent. Results are summarized in the Table 2.
2.3. Molecular modeling studies
The binding models of synthesized scaffold 3a–3h in the
enzyme active site of COX-II were depicted in Fig. 1. To
pre-assess the anti-inﬂammatory behavior of our benzimid-
azole derivatives 3a–3h on a structural basis automated dock-
ing studies were carried out using MDS v 3.5 program
(Chhajed et al., 2010). The scoring functions and hydrogen
bonds formed with the surrounding amino acids are used to
predict their binding modes, their binding afﬁnities and orien-
tation of these compounds at the active site of the COX-II en-
zyme (pdb code: 3NT1) (Kelsey and Duggan, 2010). Genetic
algorithm implemented in MDS has been successfully em-
ployed to dock inhibitors into the catalytic site of the
COX-II and to well correlate the obtained binding score with
inhibitory activities of compounds. Obtained results were eval-Table 2 The anti-inﬂammatory activity of the tested compounds (2
Treatment Mean increase in paw volume (mL)
0 h 1 h 2 h
Control 0.61 ± 0.01 1.18 ± 0.009 1.37 ± 0.0
Nimesulide 0.55 ± 0.007 0.61 ± 0.009** 0.74 ± 0.0
3a 0.544 ± 0.01 0.58 ± 0.015** 0.73 ± 0.0
3b 0.53 ± 0.013 0.73 ± 0.01* 0.88 ± 0.0
3c 0.542 ± 0.012 0.65 ± 0.03** 0.97 ± 0.0
3d 0.534 ± 0.012 0.58 ± 0.018** 0.91 ± 0.0
3e 0.55 ± 0.015 0.57 ± 0.0012** 0.64 ± 0.0
3f 0.48 ± 0.018 0.54 ± 0.015** 0.73 ± 0.0
3g 0.562 ± 0.001 0.60 ± 0.02** 0.74 ± 0.0
3h 0.55 ± 0.012 0.61 ± 0.006** 0.66 ± 0.0
Data represent mean values SEM± of ﬁve mice per group and the perc
Data were analyzed using one-way ANOVA followed by Dunnett test **
Percent edema inhibition was calculated as regards control group.
SEM-Standard Error of Mean.
The P value is <0.0001, considered extremely signiﬁcant.
* Signiﬁcant difference from the control value at p<0.001.
** Signiﬁcant difference from the control value at p< 0.01.uated in terms of binding score into the catalytic site of COX-
II. Smaller dock score indicates larger binding afﬁnity of li-
gand for receptor. Results are summarized in the Table 3.
3. Conclusion
Compounds 3-chloro-4-substituted-1-(2-(1H-benzimidazol-2-
yl)phenyl))-azetidin-2-ones 3a–3h can be easily prepared in
good yields. Purity of the compound was ascertained by analyt-
ical thin layer chromatography. Structures of synthesized
compounds were conﬁrmed by analytical (C, H and N) and
spectral techniques (IR, MASS and 1H NMR). Further com-
pounds were screened for their analgesic and anti-inﬂammatory
activity. Compound 1-(2-(1H-benzo[d]imidazol-2-yl)phenyl)-3-
chloro-4-(4-hydroxyphenyl)azetidin-2-one (3e) is found to be
possess good analgesic and anti-inﬂammatory activity i.e.%
analgesia is 46.02 as compared to 52.54 of nimesulide and
66.5% anti-inﬂammatory activity as compared to 51% of stan-
dard drug nimesulide. Compound 1-(2-(1H-benzo[d]imidazol-
2-yl)phenyl)-3-chloro-4-(4-methoxyphenyl)azetidin-2-one 3h is
found to possess good analgesic activity i.e. 43.67% and
46.7% anti-inﬂammatory activity. It is clear from the biologi-
cal screening that para hydroxy and para methoxy substituted
phenyl ring at fourth position of azetidinone ring is essential
for analgesic and anti-inﬂammatory activity. Halogen substi-
tuted phenyl ring present at fourth position of azetidinones re-
sults in compounds with poor analgesic and anti-inﬂammatory
activity. Further unsubstituted phenyl ring present at fourth
position of azetidinones results in compound with moderate
analgesic and anti-inﬂammatory activity.
Compounds 3a–3h were docked into the active site of en-
zyme COX-II. Binding energy (dock score) obtained for com-
pounds 3a, 3e, 3 h, and standard are 10.32, 11.82, 12.74
and 10.11, respectively against COX-II enzyme. Smaller
dock score (binding energy) shows strong afﬁnity toward the
receptor. Compounds 3a, 3e, and 3 h have good afﬁnity for
receptor COX-II. It is evident from the pharmacological
screening data that compounds 3e, and 3 h are potent analge-
sic anti-inﬂammatory agents where as compound 3a is a
moderately active analgesic and anti-inﬂammatory agent as0 mg/kg b.w) and Nimesulide (20 mg/kg b.w).
% Decrease in paw volume at 3 h
3 h
09 1.63 ± 0.01 –
08** 0.81 ± 0.006** 51
2** 0.94 ± 0.03** 43.4
1** 1.28 ± 0.04** 21.5
2** 1.26 ± 0.02** 22.7
6** 1.27 ± 0.03** 22.02
12** 0.71 ± 0.01** 66.5
21** 0.85 ± 0.01** 41
1** 0.92 ± 0.01** 44.5
2** 0.87 ± 0.03** 46.7
ent changes versus 1, 2 and 3 h post-carrageenan injection.
p< 0.01.
Figure 1 Best poses, orientations, hydrogen bond formed, and charge interactions of synthesized compounds 3a–3h with enzyme COX-
II. (a) Molecule 3a into the active site of enzyme COXII. It has binding score of 10.32 and shows hydrogen bonding between O of 2-oxo
of 2-azetidinone ring and 409 Serine. (b) Molecule 3h into the active site of enzyme COX-II showing hydrogen bonding between O of
methoxy and N of benzimidazole ring with glycine 533 and arginine 376, respectively. It has binding score 12.74 kJ/mole. (c) Molecule 3f
into the active site of enzyme showing hydrogen bonding between nitrogen and oxygen of azetidinone with arginine 376 and also between
nitrogen of benzimidazole ring and glycine 533. (d) Molecule 3b into the active site of enzyme CoX-II.
Table 3 Molecular docking showing binding score of synthe-
sized compounds in the active site of enzymes COX-II.
Treatment Dock score*
Nimesulide 10.11
3a 10.32
3b 06.10
3c 09.37
3d 04.83
3e 11.82
3f 07.01
3g 07.18
3h 12.74
* Dock score is binding energy in kilojoules per mole.
S1782 S.S. Chhajed, C.D. Upasanicompared to standard nimesulide. In conclusion good correla-
tion is found between in silico molecular docking experiments
and biological screening.
4. Experimental
4.1. Materials and methods
Melting points were determined on a Thomas–Hoover melting
point apparatus and are uncorrected. IR spectra were recorded
on a Jasco infrared spectrometer in KBr. 1H NMR was
recorded by a Brucker Avance II 400 spectrophotometer at a
frequency of 400.13 MHz. The electrospray mass spectra were
recorded on MICROMASS QUATRO II triple quadrapolemass spectrophotometer. All the synthesized compounds were
analyzed satisfactorily for C, H and N by Elementar Vario EL
III elemental analyzer. Analytical thin layer chromatography
(TLC) was performed by using adsorbent silica gel G, visuali-
zation of the developed chromatogram was performed with io-
dine vapors. Solvents and reagents obtained from commercial
sources were used without puriﬁcation.
4.2. Synthesis of 2-(1H-benzimidazol-2-yl)-benzenamine (1)
In 250 ml round bottom ﬂask, 0.01 M (1.08 g) O-phenylenedi-
amine was taken; to it was added 20 mL of ethylene glycol.
O.03 M (4.11 g) anthranilic acid and 2–3 drops of polyphospho-
ric acid ware added. The reaction mixture was heated on sand
bath at about 190–195 C for 4 h. The reaction mixture was
poured into crushed ice. Precipitate formed was ﬁltered, washed
with cold water, dried and recrystallized from ethanol. Yield:
(77%). M.p: 190–192 C, Rf : 0.62 [benzene: ethyl acetate
(9:1)], IR (KBr, cm1) 3360.41–3270.26 (asymmetric and sym-
metric NAH str respectively), 1609.02 (NAH def),1250.33
(CAN str). 1H NMR (400 MHz, CDCl3): d 9.9 (s, 1H,ANHA),
d 6.6–8.9 (M, 8 ArAH) d 3.97 (s 2H, ArANH2).
4.3. General procedure for synthesis of 2-(1H-benzimidazol-2-
yl)-N-[un/substituted-benzylidene] benzenamine
Equimolar quantities of unsubstituted/substituted aromatic
aldehydes and 2-(1H-benzimidazol-2-yl)-benzenamine were
dissolved in 20 mL of warm dry ethanol. To it was added
1–2 drops of concentrated sulfuric acid and heated at reﬂux
Synthesis and in-silico molecular simulation S1783for 3 h on water bath. After standing for approximately one
hour at room temperature (r.t), the crystalline product was
separated by ﬁltration, dried.
4.3.1. 2-(1H-benzimidazol-2-yl)-N-benzylidenebenzenamine
(2a)
C20H15N3, Yield 76%, m.p: 237–239 C, IR (KBr cm1)
3260.38 (NAH str ring), 3030.21 (CAH str aromatic),
1635.27 (C‚N str imine), 1H NMR: d 6.6–9.1 (m, ArAH), d
8.11 (s, 1H, N‚CHA), d 5.01 (s, ring NAH). m/e: 297.
4.3.2. N-(2-chlorobenzylidene)-2-(1H-benzimidazol-2-
yl)benzenamine (2b)
C20H14ClN3, Yield 65%, m.p: 154–156 C, IR (KBr cm1):
3310.35 (NAH str ring), 3134.37 (Aromatic CAH str),
1653.07 (C‚N str of imines), 750.23 (CACl str). 1H NMR: d
6.5–8.7 (m, 12H, ArAH), d 8.12 (s, N‚CHA), d 5.08 (s,
ANAH). m/e: 331.
4.3.3. N-(4-chlorobenzylidene)-2-(1H-benzimidazol-2-
yl)benzenamine (2c)
C20H14ClN3, Yield 57%, m.p: 202–204 C, IR (KBr cm1):
3066.03 (aromatic C–H stretching) 1648.62 (C‚N str of imi-
nes), 1657.35 (aromatic C‚C str), 645.54 (CACl str). 1H
NMR: d 6.8–8.8 (m, 12H, ArAH), d 7.16 (s, N‚CHA), d
4.02 (s, 1H, ANAH), m/e: 331.
4.3.4. N-(4-ﬂuorobenzylidene)-2-(1H-benzimidazol-2-
yl)benzenamine (2d)
C20H14FN3Yield 66%, m.p: 176–178 C, IR (KBr cm1):
3317.26 NAH str (Sec Amines), 1642.89(Aromaic C‚C str),
1500.33 NAH def. 1656.76 C‚N str imine), 1H NMR: d 8.0
(s, N‚CHA), d 6.5–7.5 (m, 12H, ArAH), d 5.1 (s, ANAH).
m/e= 316.
4.3.5. 4-[-{[2-(1H-benzimidazol-2-yl)phenyl]imino}methyl]
phenol(2e)
C20H15N3O, Yield 70%, m.p: 259–261 C, IR (KBr cm1)
3509.42 (OAH stretching), 3460.92 (NAH stretching ring),
3030.31 (Aromatic C–H stretching), 1690.62 (Imines C‚N
Stretching), 1H NMR: d 9.86 (s, 1H, ArAOH), d 7.13 (s,
N‚CHA), d 6.5–7.7 (m, 12H,ArAH), d 3.92 (s, 1H, ring-
NH), m/e:313.
4.3.6. 2-[-{[2-(1H-benzimidazol-2-yl)phenyl]imino}methyl]
phenol (2f)
C20H15N3O,Yield 70%, m.p: 122–124 C, IR (KBr cm1)=
3398.67 OAH str. 3252.22 NAH str (Sec Amines), 1651.10
(Aromaic C‚C str), 1664.00 C‚N str imine) 1500.33 NAH
def. (sec amines), 1298.83 CAN str.
1H NMR: d 9.52 (s, 1H, ArAOH), d 6.5–9.2 (m,
12H,ArAH), d 8.12 (s, N‚CHA), d 5.02 (s, 1H,ArAOAH),
d 4.00 (s, 1H,ring NAH), m/e:313.
4.3.7. N-(2-nitrobenzylidene)-2-(1H-benzimidazol-2-yl)
benzenamine(2g)
C20H14N4O2,Yield 70%, m.p: 77–79 C, IR (cm1): 3460.84
(NAH str ring), 3030.21 (CAH str aromatic), 1690.27–
1590.83 (C‚N str imine), 1555.91–1487.11 (N‚O str), 1H
NMR: d 6.5–8.5 (m, 12H, ArAH), d 7.00 (s, N‚CHA), d
5.02 (s, 1H, ANAH), m/e: 342.4.3.8. N-(4-methoxybenzylidene)-2-(1H-benzimidazol-2-
yl)benzenamine (2h)
C21H17N3O, Yield 65%, m.p: 240–242 C, IR (KBr cm1):
3509.22 (NAH stretching) 3029.03 (Aromatic C–H stretching),
1693.23 (imines C‚N stretching), 1460.27 (AOCH3 stretch-
ing), 1100.62 (CAO str). 1H NMR: d 6.8–9.1 (m, 12H, ArAH),
d 8.85 (s, N‚CHA), d 3.8 (s, 3H,AOCH3), d 3.8 (s,
1H,ANAH). m/e: 328.
4.4. General procedure for synthesis of 1-(2-(1H-benzimidazol-
2-yl)phenyl)-3-chloro-4-[(un)/substituted phenyl)]azetidin-2-
one
To 0.01 M various 2-(1H-benzimidazol-2-yl)-N-[Un/substitut-
edbenzylidene]benzenamines, was added 20 ml of 1,4 diox-
ane.The mixture was warmed to dissolve, the resultant
solution was allowed to cool, and to it was added 0.01 M tri-
ethyl amine and 0.01 M chloroacetyl chloride dropwise and
with stirring. Mixture was reﬂuxed on the boiling water bath
for 4 h. Allowed to cool and ﬁltered at pump, air dried.
4.4.1. 1-(2-(1H-benzimidazol-2-yl)phenyl)-3-chloro-4-
phenylazetidin-2-one (3a)
C22H16ClN3O, Yield: 76%, m.p: 276–278 C, IR (KBr cm1):
3061.06 (aromatic CAH str), 1751.42(C‚O str
amides),1248.67 600 (CAlCl str). 1H NMR (CDCl3): d 6.9–
8.3 (m, 13H, ArAH) d 5.7 (s, 1H, C3AH), d 5.4 (s, 1H,
C4AH), d 4.4 (s, 1H, ANH), m/e: 373, C‚70.61%, H=,
4.30%, and N = 11.19%.
4.4.2. 1-(2-(1H-benzimidazol-2-yl)phenyl)-3-chloro-4-(2-
chlorophenyl)azetidin-2-one (3b)
C22H15Cl2N3O, Yield: 65%, m.p: 154–156 C, IR (KBr cm1):
3232.80 (NAH stretching secondary amine), 3066.06 (Aro-
matic CAH str), 1749.49 (C‚O str amides), 734.90 (CACl
str). 1H NMR (CDCl3): d 6.7–8.6(m, 12H,ArAH), d 5.5 (s,
1H, C3AH), d 5.2 (s, 1H, C4AH), d 4.2 (s,1H,ANAH),
m/e:408, C = 64.69%, H=, 3.66%, and% N= 10.25.
4.4.3. 1-(2-(1H-benzimidazol-2-yl)phenyl)-3-chloro-4-(4-
chlorophenyl)azetidin-2-one (3c)
C22H15Cl2N3O, Yield: 57%, m.p: 202–204 C, IR (cm
1) = 3314.66(NAH str), 1747.34(C‚O str of cyclic amide),
3119.28 (aromatic CAH str) 2934.72 and 2889.02(asymmetric
and symmetric CAH str), 786.34 (CACl str). 1H NMR
(CDCl3): d 6.7–8.6(m, 12H, ArAH) d 5.2 (s, 1H, C3AH), d
4.9 (s, 1H, C4AH), d 4.1 (s, 1H, NAH), m/e: 408,
C = 64.67%, H=, 3.69%, and N = 10.17%.
4.4.4. 1-(2-(1H-benzimidazol-2-yl)phenyl)-3-chloro-4-(4-
ﬂuorophenyl)azetidin-2-one (3d)
C22H15ClFN3O, Yield: 60%, m.p: 109–111 C, IR (KBr cm1):
3353.98 (NAH str), 3151.47 (Aromatic CAH str), 2956,
3008.35 (asym. and sym. CAH str), 1733.48 (C‚O str amides).
1H NMR (CDCl3): d6.8–8.5(m, 12H, ArAH), d 5.58 (s, 1H,
C3AH), d 5.09 (s, 1H, C4AH), d 4.10 (s, 1H, NAH), m/e: 391,
C = 67.37%, H=, 3.85%, and N = 10.69%.
4.4.5. 1-(2-(1H-benzimidazol-2-yl)phenyl)-3-chloro-4-(2-
hydroxyphenyl)azetidin-2-one (3e)
C22H16ClN3O2, Yield: 70%, m.p: 92–94 C, IR (KBr cm1):
3305.12 (OAH str), 3157.36 (Aromatic CAH str), 2937.82
S1784 S.S. Chhajed, C.D. Upasaniand 2900.28 (asym.and sym. CAH str), 1749.32 (C = 0 str of
amides), 600 (CACl str) 1H NMR (CDCl3): d 9.62 (s, 1H,
ArAOH), d 6.7–7.9 (m, 12H, ArAH), d 5.44 (s, 1H, C3AH),
d 5.00 (s, 1H, C4AH), d 4.20 (s, 1H, ANH), m/e:389,
C = 67.77%, H=, 4.39%, and N = 10.74%.
4.4.6. 1-(2-(1H-benzimidazol-2-yl)phenyl)-3-chloro-4-(4-
hydroxyphenyl)azetidin-2-one (3f)
C22H16ClN3O2, Yield: 55%, m.p: 197–199 C, IR (KBr cm
1):3314.66 (OAH str), 1747.34 (C‚O str of cyclic amide),
3119.28 (Aromatic CAH str) 2934.72 and 2889.02 (asymmetric
and symmetric CAH str), 786.34 (CACl str). 1H NMR
(CDCl3): d 9.99 (s, 1H, ArAOH), d 6.7–7.9 (m, 12H, ArAH),
d 5.44 (s, 1H, C3AH), d 5.00 (s, 1H, C4AH), d 4.10 (s, 1H,
ANH), m/e: 389, C = 67.75%, H=, 4.37%, and
N= 10.69%.
4.4.7. 1-(2-(1H-benzimidazol-2-yl)phenyl)-3-chloro-4-(2-
nitrophenyl)azetidin-2-one (3g)
C22H15ClN4O3, Yield: 70%, m.p: 123–125 C, IR (KBr cm1):
3377.45 (NAH str), 3099.7 (aromatic CAH str), 2951.19 and
2912.61 (asym.and sym. CAH str), 1739.13 (C = 0 str of
amides), 638.46 (CACl str),1508.38 and 1473.66 (N‚O str
asymmetric and symmetric), 1H NMR (CDCl3): d 6.9–8.4
(m, 12H, ArAH), d 5.8 (s, 1H, C3AH), d 5.6 (s, 1H, C4AH),
d 3.85 (s, 1H, ANH), m/e:418, C = 63.05%, H=, 3.59%,
and N = 13.35%.
4.4.8. 1-(2-(1H-benzimidazol-2-yl)phenyl)-3-chloro-4-(4-
methoxyphenyl)azetidin-2-one (3h)
C23H18ClN3O2, Yield: 45%, m.p: 67–69 C, IR (KBr cm1):
3260.35 (NAH stretching ring), 3151.79 (aromatic CAH str),
1695.07 (C‚O str of amide), 1255 and 1045.45 (CAO str of
phenyl alkyl ether). 750.42 (CACl Str) 1H NMR (CDCl3):
d6.9–8.9 d 5.5 (s, 1H, C3AH), d 5.1 (s, 1H, C4AH), d 4.41
(s, 1H, ANH), (m, 12H, ArAH), d 3.74 (s, 3H, AOCH3), m/
e: 403, C = 68.33%, H=, 4.46%, and N= 13.37%.
4.5. Pharmacology
4.5.1. Analgesic activity
The analgesic validation of tested compounds was evaluated
using the acetic acid-induced writhing method. Mice (25–
30 g) were used in groups, each containing ﬁve animals. The
1st group was kept as a control (received the vehicle) while
the 2nd one was subcutaneously injected with nimesulide in
a dose of 20 mg/kg (standard). The other groups were injected
with the tested compounds in doses 20 mg/kg body weight.
Writhing was induced 30 min later, by intraperitoneal injection
of 0.1 ml of 0.6% acetic acid. Numbers of writhes (abdominal
contractions) in all animals were counted for 20 min, immedi-
ately after acetic acid injection (0 time) and hourly after
administration for 4 h. Analgesic activity was expressed as
the percentage protection against writhing produced by the
new compounds all over the experimental period comparing
between control and those pretreated with the new compounds
using the ratio,
[(No of writhing in control group – No of writhing in trea-
ted group)/No of writhing in control group]·100.
4.5.2. Anti inﬂammatory activity
The anti-inﬂammatory effect of the newly synthesized
compounds was evaluated in correspondence to the carra-geenan-induced paw edema method. Groups of animals each
consisting of ﬁve rats weighing 180–200 g were used. The 1st
group was treated with the vehicle and left as control while
the 2nd one was given nimesulide by subcutaneous injection
in a dose of 20 mg/kg body weight. Other groups were admin-
istered orally the tested compounds in doses 20 mg/kg body
weight. After 30 min, acute inﬂammation was induced by sub-
plantar injection of 0.1 ml of 1% suspension of carrageenan in
the right hind paw of all rats. The volume of the paw was mea-
sured plethysmographically immediately 1, 2 and 3 h after the
injection of the irritant. The difference in volume gave the
amount of edema developed. Percent inhibition of the edema
between the control group and compound treated groups
was calculated and compared with that of the group receiving
a standard drug.
4.6. In-silico molecular docking
Molecular docking of compounds 3a–3h into the three-dimen-
sional X-ray structure of COX-II (PDB code: 3NT1) was car-
ried out using the molecular design Suite (MDS) software
package (v. 3.5). The protein–ligand complex was constructed
based on the X-ray structure COX-II. All compounds were
built using Chem Draw Ultra v.8.0 and minimized using the
Merck Molecular Force Field. Keeping program parameters
to their default values, the docking was performed using
Molecular Design Suite (MDS) into the 3D model of the cat-
alytic site of COX-II. Genetic algorithm implemented in MDS
has been successfully employed to dock inhibitors into the cat-
alytic site of the enzyme. The obtained binding score was
found to be in good agreement with inhibitory activities of
respective compounds. Comparative docking experiments of
compounds 3a–3h with known COX-II inhibitor agent such
as nimesulide were performed. Obtained results were evaluated
in terms of binding score into the catalytic site of enzymes.Acknowledgements
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